Last reviewed · How we verify
Sevoflurane + Remifentanyl
Sevoflurane + Remifentanyl is a General anesthetic and opioid analgesic Small molecule drug developed by Azienda Ospedaliera San Gerardo di Monza. It is currently in Phase 3 development for General anesthesia for surgical procedures.
Sevoflurane is a general anesthetic that induces unconsciousness and amnesia, while Remifentanil is a potent opioid analgesic that provides pain relief.
Sevoflurane is a small molecule that acts as a positive modulator of the glycine receptor (alpha-1/beta). It is used in total intravenous anesthesia, which is an intervention studied in clinical trials for various conditions, including rhinosinusitis chronic, sinus cancer, and myocardial ischemic reperfusion injury.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sevoflurane + Remifentanyl |
|---|---|
| Sponsor | Azienda Ospedaliera San Gerardo di Monza |
| Drug class | General anesthetic and opioid analgesic |
| Target | GABA_A receptor and opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Sevoflurane works by inhibiting the activity of neurons in the brain, leading to a loss of consciousness. Remifentanil, on the other hand, binds to opioid receptors in the brain and spinal cord, reducing the perception of pain.
Approved indications
- General anesthesia for surgical procedures
Common side effects
- Respiratory depression
- Nausea and vomiting
- Hypotension
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Equivalent MAC in General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- qCON/qNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery (NA)
- Low-Flow Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy (NA)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- Continuous Versus 1-min Oscillometric Arterial BP Monitoring (NA)
- The Effects of Three Different Anesthetic Methods on Postoperative Agitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevoflurane + Remifentanyl CI brief — competitive landscape report
- Sevoflurane + Remifentanyl updates RSS · CI watch RSS
- Azienda Ospedaliera San Gerardo di Monza portfolio CI
Frequently asked questions about Sevoflurane + Remifentanyl
What is Sevoflurane + Remifentanyl?
How does Sevoflurane + Remifentanyl work?
What is Sevoflurane + Remifentanyl used for?
Who makes Sevoflurane + Remifentanyl?
What drug class is Sevoflurane + Remifentanyl in?
What development phase is Sevoflurane + Remifentanyl in?
What are the side effects of Sevoflurane + Remifentanyl?
What does Sevoflurane + Remifentanyl target?
Related
- Drug class: All General anesthetic and opioid analgesic drugs
- Target: All drugs targeting GABA_A receptor and opioid receptors
- Manufacturer: Azienda Ospedaliera San Gerardo di Monza — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for General anesthesia for surgical procedures
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing